Search This Blog

Tuesday, June 30, 2026

BioCryst to end internal discovery, cuts 2026 non-GAAP opex guidance

 

BioCryst to end internal discovery, close Birmingham research site, cuts 2026 non-GAAP opex guidance to $420–$440 million

  • Strategic shift emphasizes external innovation after ending internal discovery programs and Birmingham, Alabama research facility operations.
  • Company reaffirmed its revenue guidance while lowering 2026 non-GAAP operating expense guidance to $420–$440 million.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)